We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -2.23 | -0.29% | 768.89 | 775.63 | 767.10 | 771.68 | 283,049 | 15:12:02 |
From May 2019 to May 2024
By Chelsey Dulaney
Eli Lilly (LLY) and Co. and Incyte Corp. (INCY) said Monday that a late-stage study of an experimental rheumatoid arthritis treatment showed improvement over a placebo and met its primary endpoint.
The companies said patients taking the drug, baricitinib, showed a statistically signficant improvement compared to those taking a placebo in the second-consecutive Phase 3 trial. The trial, part of an extensive Phase 3 program to test the drug in more than 3,000 patients, included 684 patients who had showed inadequate responses to conventional drugs.
The companies announced similar results in December from the first Phase 3 trial.
Rheumatoid arthritis is an autoimmune disease characterized by inflammation and progressive destruction of joints.
Lilly and Incyte struck a world-wide license and collaboration agreement for baricitinib in 2009. In addition to arthritis studies, the drug is also being tested for the treatment of psoriasis and diabetic nephropathy.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
